BPC-157 Complete Guide: Dosage, Protocols & Evidence (UK 2026)

BPC-157 is arguably the most researched tissue repair peptide in current use among athletes. Its capacity to accelerate tendon, ligament, muscle, and gut healing in animal models has generated significant interest among athletes dealing with the joint and connective tissue injuries that accumulate with heavy training — and particularly among those using anabolic steroids, where rapid muscle strength gains can outpace connective tissue adaptation. This guide covers the current evidence base, dosing protocols, and practical administration for UK athletes.

What Is BPC-157?

BPC-157 (Body Protection Compound 157) is a synthetic 15-amino acid peptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a partial sequence of body protection compound found naturally in human gastric juice. It was isolated and synthesised by researchers in the 1990s and has been the subject of extensive animal research, predominantly from research groups in Croatia at the University of Zagreb.

BPC-157 has not completed Phase III human clinical trials and is not approved for human use by any major regulatory agency. It is classified as a research chemical in most jurisdictions, including the UK. The evidence base for human use consists of animal studies, case reports, and anecdotal reports from users — not controlled human trials. This is an important caveat when evaluating the evidence.

Mechanisms of Action

BPC-157's tissue repair properties appear to operate through multiple mechanisms:

• VEGF upregulation: BPC-157 stimulates vascular endothelial growth factor (VEGF), promoting angiogenesis — the formation of new blood vessels. New vasculature delivers oxygen and nutrients to injury sites, accelerating healing.
• Growth hormone receptor interaction: Evidence suggests BPC-157 modulates GH receptor expression at injury sites, potentially amplifying local GHR-mediated tissue repair signalling.
• Fibroblast proliferation: Stimulates fibroblast activity — the cells responsible for producing collagen and extracellular matrix components — accelerating connective tissue repair.
• Nitric oxide pathway modulation: BPC-157 affects NO signalling in a way that protects against ischaemia-reperfusion injury and promotes vasodilation at injury sites.
• Gut mucosal protection: The original research on BPC-157 focused on its gastroprotective properties — it protects gut mucosa against NSAID damage, alcohol-induced injury, and inflammatory bowel conditions in animal models.

What Can BPC-157 Treat? Evidence Summary

Tissue / Condition	Animal Evidence	Human Evidence	Practical Use
Tendon injuries	Strong (multiple studies)	Limited (anecdotal)	High (local injection near injury)
Ligament tears	Strong	Very limited	High (local or systemic)
Muscle tears	Moderate	Very limited	Moderate
Gut / GI tract	Very strong (origin of research)	Phase II trials completed for IBD	High (oral BPC-157 for gut use)
Bone healing	Moderate	None established	Low
NSAID-induced gut injury	Strong (protective)	Early trials positive	Promising (oral capsules)

BPC-157 Dosing Protocol

Standard Systemic Protocol (Subcutaneous Injection)

• Dose: 250–500 mcg per day
• Frequency: Once or twice daily
• Route: Subcutaneous injection (abdominal fat or near the injury site)
• Duration: 4–12 weeks depending on injury severity

Local Injection Protocol (Near Injury Site)

• Dose: 200–400 mcg per injection
• Location: Subcutaneously adjacent to the injury — not into a joint or tendon directly
• Frequency: Daily or every other day
• Caution: Injecting into or adjacent to joint spaces without medical guidance carries infection and local tissue risk

Oral Protocol (Gut Health)

• Dose: 250–500 mcg per day in oral capsule form
• Note: Oral BPC-157 is believed to act primarily on the gastrointestinal tract. Systemic bioavailability via oral route is uncertain — for systemic injury healing, subcutaneous injection is preferred.

BPC-157 + TB-500 Stack

The most popular peptide combination for injury recovery combines BPC-157 with TB-500. The rationale: BPC-157 excels at local tissue repair and gut protection; TB-500 distributes systemically and promotes broader angiogenesis and muscle cell regeneration. Together they address injury recovery from complementary angles. See our TB-500 complete guide for TB-500 protocols and see our complete peptides guide for full context.

Reconstitution Guide

BPC-157 is typically supplied as lyophilised powder in 5 mg vials. To reconstitute to 500 mcg/ml concentration: add 10 ml of bacteriostatic water. Each 1 ml injection then contains 500 mcg. For 250 mcg doses: inject 0.5 ml. Store reconstituted BPC-157 refrigerated; use within 28 days. Browse BPC-157 and all peptide products.

Safety and Side Effects

• No significant adverse effects have been documented in animal studies even at doses orders of magnitude higher than performance doses
• No hormonal effects: BPC-157 does not affect testosterone, GH, IGF-1, cortisol, or any other measurable hormone in standard animal studies
• No HPG suppression: No PCT required
• Injection site reactions: Minor bruising or soreness from the injection itself is possible, particularly with local injections near injury sites
• Long-term human safety: Unknown — no long-term human clinical data

Frequently Asked Questions

How fast does BPC-157 work?

Animal study timelines suggest accelerated healing compared to untreated controls within 2–4 weeks. Anecdotal reports from athletes vary widely: some report noticeable pain reduction and improved function within 1–2 weeks; others notice improvements after 4–6 weeks. Tendon injuries (which have poor baseline vascularity) may show slower response than muscle tears.

Can BPC-157 be used while on steroids?

Yes — this is a common application. Athletes using anabolic steroids often use BPC-157 concurrently to support the connective tissue and joint stress that comes with steroid-driven rapid strength gains. BPC-157 does not interact pharmacologically with anabolic steroids in any documented way. For context on steroid cycles it can accompany, see our safe steroid use guide.

Is BPC-157 legal in the UK?

BPC-157 is not classified as a controlled substance under the Misuse of Drugs Act 1971. It exists in a regulatory grey area as a research chemical. It is not licensed for human use (no approved medicine contains BPC-157 currently). WADA lists BPC-157 as a prohibited substance in competitive sport under the “peptide hormones, growth factors, and related substances” category — athletes subject to anti-doping rules must avoid it.